ATC Group: V03AE03 Lanthanum carbonate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V03AE03 in the ATC hierarchy

Level Code Title
1 V Various
2 V03 All other therapeutic products
3 V03A All other therapeutic products
4 V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
5 V03AE03 Lanthanum carbonate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 2.25 g

Active ingredients in V03AE03

Active Ingredient Description
Lanthanum

Lanthanum is indicated as a phosphate binding agent for use in the control of hyperphosphataemia.

Related product monographs

Title Information Source Document Type  
FOSRENOL Chewable tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FOSRENOL Oral powder Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.